Al­ny­lam blames the In­fla­tion Re­duc­tion Act for a PhI­II cut — would it have sold enough for ne­go­ti­a­tions?

Al­ny­lam Phar­ma­ceu­ti­cals, the phar­ma mar­ket’s leader in RNAi ther­a­pies, re­port­ed its third quar­ter earn­ings Thurs­day, up­dat­ing share­hold­ers on its pipeline progress and ini­tial sales fig­ures for the re­cent­ly ap­proved vutrisir­an (mar­ket­ed as Amvut­tra).

But tucked away near the bot­tom of its re­port, the com­pa­ny re­vealed it would scrap plans to launch a Phase III tri­al for vutrisir­an in the rare Star­gardt dis­ease, ap­pear­ing to blame Pres­i­dent Joe Biden’s In­fla­tion Re­duc­tion Act in the process.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER